- Dynavax Technologies (DVAX, Financial) reports a 203% total stockholder return over the last five years.
- HEPLISAV-B® achieved $268 million in revenue in 2024, capturing 44% U.S. market share.
- Q1 2025 HEPLISAV-B® revenue saw a 36% year-over-year increase to $65 million.
Dynavax Technologies (DVAX), a leading biopharmaceutical company, has filed an investor presentation with the Securities and Exchange Commission (SEC) as it prepares for its 2025 Annual Meeting of Stockholders. The company is gearing up to defend against Deep Track Capital's proxy contest, advocating for its current strategic direction and board composition.
The company has achieved a remarkable 203% total stockholder return over the past five years, a significant outperformance compared to its vaccine peers' return of 9% and a decline of 17% in the S&P Biotechnology Select Industry Index. Dynavax's flagship product, HEPLISAV-B®, generated $268 million in net product revenue in 2024 and secured a 44% market share in the U.S.
In Q1 2025, Dynavax reported HEPLISAV-B® revenue growth of 36% year-over-year, totaling $65 million. This exceptional performance reflects the successful execution of their business model during pandemic-related developments, which generated over $950 million in revenue from 2020 to 2022.
Regarding capital management, Dynavax has completed 85% of its $200 million share repurchase program. The company opposes Deep Track's proposal to fully monetize HEPLISAV-B® and return cash to shareholders, citing potential risks to long-term growth opportunities. Dynavax continues to advocate for a balanced approach in capital allocation that facilitates both strategic growth investments and shareholder returns.
